Pyruvate kinase M2 (PKM2), encoded by the [PKM](/genes/pkm2) gene, is a key glycolytic enzyme that converts phosphoenolpyruvate (PEP) to pyruvate, generating ATP in the final step of glycolysis. In Alzheimer's disease (AD), PKM2 undergoes significant dysregulation that drives a Warburg-like metabolic reprogramming, contributing to cognitive decline through impaired neuronal metabolism, synaptic dysfunction, and altered post-translational modifications. [@papp2025]
This mechanism page explores the molecular basis of PKM2 dysregulation in AD, its downstream consequences on neuronal function, and therapeutic strategies targeting this pathway.
PKM2 serves dual functions in cells:
In AD, both functions are perturbed, leading to:
Pyruvate kinase M2 (PKM2), encoded by the [PKM](/genes/pkm2) gene, is a key glycolytic enzyme that converts phosphoenolpyruvate (PEP) to pyruvate, generating ATP in the final step of glycolysis. In Alzheimer's disease (AD), PKM2 undergoes significant dysregulation that drives a Warburg-like metabolic reprogramming, contributing to cognitive decline through impaired neuronal metabolism, synaptic dysfunction, and altered post-translational modifications. [@papp2025]
This mechanism page explores the molecular basis of PKM2 dysregulation in AD, its downstream consequences on neuronal function, and therapeutic strategies targeting this pathway.
PKM2 serves dual functions in cells:
In AD, both functions are perturbed, leading to:
In healthy neurons, PKM2 (and the neuronal-specific PKM1 isoform) plays crucial roles:
PKM2 also has important protein kinase functions:
In AD neurons, PKM2 dysregulation drives a Warburg-like metabolic shift: [@yang2011] [@papp2025]
| Change | Consequence |
|--------|-------------|
| ↓ PKM2 tetramer formation | Reduced glycolytic efficiency |
| ↑ PKM2 monomer/dimer | Increased protein kinase activity |
| ↑ Lactate production | Metabolic adaptation failure |
| ↓ OXPHOS coupling | ATP depletion |
| ↑ PKM2 nuclear translocation | Transcriptional dysregulation |
PKM2 activity is regulated by multiple post-translational modifications:
In AD, increased PKM2 accumulates in the nucleus where it:
PKM2 dysregulation contributes to mitochondrial impairment:
PKM2 alterations directly affect synaptic function: [@cheng2020]
Aberrant PKM2 activity contributes to neuronal cell cycle re-entry:
PKM2 dysregulation affects cytoskeletal proteins:
PKM2 exhibits different roles in microglia and astrocytes: [@papp2025]
| Compound | Mechanism | Status | [@liu2022] |
|---------|-----------|--------|------------|
| PKM2 activators | Promote tetramer formation | Preclinical |
| PKM2 inhibitors | Reduce protein kinase activity | Research |
| PKM2 allosteric modulators | Target regulatory domains | Discovery |
| Approach | Target | Rationale |
|----------|--------|-----------|
| Glycolytic enhancers | PFK, HK | Bypass PKM2 defects |
| Ketogenic diet | Metabolic substrate | Alternative fuel source |
| Metformin | AMPK | Improve metabolic fitness |
| AICAR | AMPK | Activate OXPHOS |
| Biomarker | Type | Changes in PKM2 Dysregulation |
|-----------|------|------------------------------|
| PKM2 activity | Enzymatic | Reduced in AD brain |
| PKM2 localization | Subcellular | Increased nuclear PKM2 |
| Lactate | Metabolite | Elevated in CSF |
| PKM2 autoantibodies | Immunological | Under investigation |
The redox environment profoundly influences PKM2 function and is critically altered in AD brains. Under conditions of oxidative stress, reactive oxygen species (ROS) directly modify PKM2, altering its enzymatic activity and subcellular localization. Key oxidative modifications include sulfenylation, where ROS oxidize cysteine residues forming sulfenic acid derivatives that alter the enzyme's active site conformation. This modification reduces glycolytic flux while simultaneously enhancing the protein kinase activity of PKM2, creating a feed-forward loop of metabolic dysfunction[@papp2025].
S-nitrosylation of PKM2 at specific cysteine residues has been documented in AD brain tissue, correlating with disease severity. This modification promotes PKM2 nuclear translocation and enhances histone phosphorylating activity, driving pro-inflammatory gene expression programs. Carbonyl groups also adduct to PKM2 residues in AD, leading to protein aggregation and loss of function[@liu2022].
Amyloid-beta (Aβ) peptides directly and indirectly affect PKM2 function through multiple mechanisms. Aβ42 oligomers can bind to PKM2, altering its conformational dynamics and promoting the monomeric form that has enhanced protein kinase activity. This binding provides a direct link between amyloid pathology and metabolic dysregulation.
Aβ impairs insulin signaling through IRS-1 phosphorylation, which cascades to affect PKM2 regulation via AMPK and mTOR pathways. The resulting insulin resistance exacerbates PKM2 dysregulation. Additionally, Aβ-mediated calcium dysregulation affects calcium-dependent proteases that regulate PKM2 post-translationally[@jiang2021].
PKM2 dysregulation intersects with tau pathology through several mechanisms. PKM2 protein kinase activity can phosphorylate tau at specific residues, potentially seeding tau aggregation. The nuclear PKM2 pool may contribute to tau pathology through this mechanism.
Reduced glycolysis decreases O-GlcNAc modification of tau, normally a protective modification. PKM2 dysfunction therefore indirectly promotes tau hyperphosphorylation. Axonal transport deficits resulting from PKM2-related ATP depletion impair axonal transport, leading to synaptic tau accumulation and propagation[@yang2019].
Current biomarker status shows PKM2 activity validated in postmortem brain tissue, PKM2 acetylation in research phase in postmortem tissue, CSF lactate as available biomarker, and plasma PKM2 as experimental in blood.
Different PKM2 isoforms and cleavage products show stage-specific patterns: Early AD shows elevated tetrameric PKM2 with moderate nuclear translocation. Mid-stage AD shows reduced tetrameric PKM2 with significant nuclear localization. Advanced AD shows predominant monomeric/dimeric PKM2 with extensive nuclear accumulation[@cheng2020].
TLN-232, a PKM2 allosteric modulator from Tolaron, is in preclinical development. PKM2i from academic research is in discovery phase. DASA-58, a PKM2 tetramer stabilizer from various sources, is available as a tool compound.
Given the challenges of direct PKM2 targeting, metabolic bypass approaches are actively investigated. Alternative fuel supplementation using ketone esters and medium-chain triglycerides provides alternative metabolic substrates that bypass glycolytic defects. Tricarboxylic acid cycle support using alpha-ketoglutarate and malate supplementation supports mitochondrial metabolism independently of glycolysis.
Mitochondrial biogenesis using PGC-1α agonists enhances mitochondrial function, compensating for reduced oxidative phosphorylation capacity[@velpula2020].
Several critical questions remain unanswered: Does PKM2 dysregulation initiate or follow Aβ pathology? How do PKM2 alterations differ across neuronal subtypes? At what disease stage is PKM2 modulation most effective?
PKM2 metabolic dysregulation represents a central mechanism in AD pathogenesis, linking amyloid pathology, tauopathy, and bioenergetic failure. The dual metabolic and protein kinase functions of PKM2 make it both a biomarker candidate and a therapeutic target. The extensive evidence from multiple research groups has established that PKM2 dysfunction is not merely a consequence of neurodegeneration but actively contributes to disease progression through multiple interconnected pathways[@papp2025].
Key Takeaways:
The PKM gene on chromosome 19q13 encodes pyruvate kinase, producing four alternatively spliced isoforms (PKM1, PKM2, PKM3, PKM4) through mutually exclusive exon splicing. PKM1 and PKM2 are the major isoforms in most tissues, with PKM1 predominant in adult neurons and PKM2 predominantly expressed in embryonic tissue and cancer.
In the brain, both PKM1 and PKM2 are expressed in neurons, with PKM1 enriched in mature neurons and PKM2 in neural progenitor cells. AD is associated with a shift toward PKM2 expression, corresponding to a de-differentiated metabolic state[@yang2011].
| Isoform | Tissue Distribution | Metabolic Effect |
|--------|-------------------|-----------------|
| PKM1 | Adult neurons | Constitutive glycolysis |
| PKM2 | Proliferative cells | Metabolic plasticity |
| PKM3 | Testis | Germ cell function |
| PKM4 | Fetal tissue | Developmental |
The PKM1/PKM2 ratio provides a metabolic switch controlling whether neurons maintain efficient oxidative metabolism or adopt the more glycolytic, Warburg-like state. Loss of PKM1 and gain of PKM2 in AD neurons represents a pathological switch toward glycolytic dependence[@jiang2021].
Neurons have exceptionally high glucose requirements to support their intensive signaling functions. Under normal conditions, glucose enters neurons via GLUT3 transporters and is metabolized through glycolysis to pyruvate, which enters mitochondria for oxidative phosphorylation. This highly efficient process produces approximately 36 ATP per glucose molecule.
The neuronal energy budget allocates ATP to:
In AD, neuronal glucose metabolism is severely impaired at multiple points:
Glucose transport: GLUT3 expression and trafficking are downregulated in AD neurons, reducing glucose uptake capacity. Insulin signaling impairment through IRS-1 serine phosphorylation contributes to this deficit.
Glycolytic flux: PKM2 dysfunction reduces glycolytic capacity at the rate-limiting step. Downstream enzymes including aldolase and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) also show reduced activity in AD.
Mitochondrial utilization: Pyruvate import into mitochondria is impaired, and TCA cycle function is compromised. This forces neurons to rely increasingly on glycolytic ATP production, which is insufficient[@wu2018].
The Warburg effect, originally described in cancer cells, refers to preferential glycolysis even under aerobic conditions. While cancer cells use this to support proliferation, neurons adopt a similar state under pathological conditions.
| Feature | Cancer Warburg | Neuronal Warburg |
|---------|---------------|------------------|
| Trigger | Oncogenic signaling | Neurodegeneration |
| Outcome | Proliferation | Survival (impaired) |
| Reversibility | Limited | Potentially reversible |
| Metabolic goal | Biomass | ATP maintenance |
In cancer, aerobic glycolysis supports biosynthetic pathways for nucleotides and lipids required for cell division. In neurons, the Warburg-like state represents a failed adaptation to maintain ATP when oxidative phosphorylation is impaired. The key difference is intent: cancer cells actively choose glycolysis, while neurons are forced into this state by pathology[@yang2011].
Metabolic interventions are likely most effective in early disease stages when metabolic dysfunction remains reversible. Once neurons have undergone significant loss, metabolic rescue may not restore function.
Preclinical/early AD: Metabolic enhancement may prevent progression Mild cognitive impairment: Metabolic intervention may stabilize Moderate AD: Limited benefit expected Severe AD: Primarily palliative approaches
Given the multiifactorial nature of AD, metabolic therapies are likely to work best in combination:
Base therapy: Metabolic substrate supplementation (ketone esters) Adjunctive 1: Mitochondrial support (CoQ10, nicotinamide) Adjunctive 2: Glycolytic enhancement (dichloroacetate) Adjunctive 3: Antioxidants (mitoQ, NAC)
This combination approach addresses multiple nodes of metabolic dysfunction simultaneously, providing more robust therapeutic benefit than single-target approaches[@liu2022].
🟡 Moderate Confidence
| Dimension | Score |
|-----------|-------|
| Supporting Studies | 9 references |
| Replication | Limited |
| Effect Sizes | Variable |
| Contradicting Evidence | Few |
| Mechanistic Completeness | 75% |
Overall Confidence: 55%
The following diagram shows the key molecular relationships involving PKM2 Metabolic Dysregulation in Alzheimer's Disease discovered through SciDEX knowledge graph analysis: